Summary:
10 therapeutic agents are in active clinical trials. Another 15 therapeutic agents are in planning stages. Currently the three (3) most likely drugs to be safe and effective are, for critically ill COVID-19 patients: (1) Remdesivir anti-viral drug by Gilead, and (2) Actemra/RoActemra (Tocilizumab) immunosuppressive drug by Roche, and for early stage SARS-CoV-2 infection: (3) Avigan (favipiravir) anti-viral drug by Fujifilm, Japan.
Published for educational purposes and social benefit, not for profit. Not a recommendation or endorsement. Always consult your doctor for medical advice.
CELL & HOST MICROBE | SnapShot: SARS-CoV-2 antibodies
Monoclonal antibody therapies hold great promise for COVID-19; however, the recent emergence and spread of escape variants threaten to limit their value. Shown here are structural and linear representations of [...]